Acasti Pharma Retained Earnings (Accumulated Deficit) 2014-2024 | GRCE
Acasti Pharma retained earnings (accumulated deficit) from 2014 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Acasti Pharma Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024 |
$-211 |
| 2023 |
$-198 |
| 2022 |
$-156 |
| 2021 |
$-146 |
| 2020 |
$-126 |
| 2019 |
$-101 |
| 2018 |
$-56 |
| 2017 |
$-38 |
| 2016 |
$-30 |
| 2015 |
$-30 |
| 2015 |
$ |
| 2014 |
$-30 |
| 2014 |
$ |
| 2013 |
$-20 |
| 2013 |
$ |
Acasti Pharma Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-214 |
| 2024-03-31 |
$-211 |
| 2023-12-31 |
$-208 |
| 2023-09-30 |
$-206 |
| 2023-06-30 |
$-202 |
| 2023-03-31 |
$-198 |
| 2022-12-31 |
$-169 |
| 2022-09-30 |
$-165 |
| 2022-06-30 |
$-160 |
| 2022-03-31 |
$-156 |
| 2021-12-31 |
$-152 |
| 2021-09-30 |
$-148 |
| 2021-06-30 |
$-149 |
| 2021-03-31 |
$-146 |
| 2020-12-31 |
$-140 |
| 2020-09-30 |
$-137 |
| 2020-06-30 |
$-131 |
| 2020-03-31 |
$-126 |
| 2019-12-31 |
$-136 |
| 2019-09-30 |
$-124 |
| 2019-06-30 |
$-101 |
| 2019-03-31 |
$-101 |
| 2018-12-31 |
$-81 |
| 2018-09-30 |
$-78 |
| 2018-06-30 |
$-62 |
| 2018-03-31 |
$-56 |
| 2017-12-31 |
$-50 |
| 2017-09-30 |
$-46 |
| 2017-06-30 |
$-40 |
| 2017-02-28 |
$-38 |
| 2016-11-30 |
$-36 |
| 2016-08-31 |
$-35 |
| 2016-05-31 |
$-33 |
| 2016-03-31 |
$-33 |
| 2016-02-29 |
|
| 2015-12-31 |
$-29 |
| 2015-09-30 |
$-28 |
| 2015-06-30 |
$-28 |
| 2015-03-31 |
$-30 |
| 2014-12-31 |
$-28 |
| 2014-09-30 |
$-31 |
| 2014-06-30 |
$-28 |
| 2014-03-31 |
$-30 |
| 2014-02-28 |
|
| 2013-12-31 |
$-28 |
| 2013-09-30 |
$-24 |
| 2013-06-30 |
$-22 |
| 2013-03-31 |
$-20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
